Literature DB >> 19018026

Bacterial DNA and its consequences in patients with cirrhosis and culture-negative, non-neutrocytic ascites.

Mohammed Mahmoud El-Naggar1, El-Sayed Abdul-Maksoud Khalil2, Medhat Abdul Massih El-Daker1, Mona Fouda Salama1.   

Abstract

The detection of bacterial DNA in serum and ascitic fluid (AF) from patients with liver cirrhosis and ascites is interpreted as molecular evidence of intestinal bacterial translocation (BT) and considered sufficient to activate the cellular immune response leading to greater cytokine synthesis. We studied 34 patients with liver cirrhosis and culture-negative, non-neutrocytic ascites [22 patients without bacterial DNA (group I) and 12 patients with bacterial DNA (group II)]. History and clinical examination were done with the following investigations at first admission and followed up for 24 weeks: serum and AF tumour necrosis factor-alpha (TNF-alpha), AF polymorphonuclear leukocytes, AF cultivation and detection of blood and AF bacterial DNA. Serum and AF TNF-alpha were significantly higher in patients with bacterial DNA compared to those without bacterial DNA at first admission [54.5+/-22.56 vs 35.2+/-17.97 pg ml(-1) (P=0.02) and 123.2+/-49.32 vs 82.6+/-29.58 pg ml(-1) (P <0.005), respectively]. These changes became highly significant at the end of follow-up of both groups [119.3+/-27.19 vs 40.2+/-16.08 pg ml(-1) (P <0.001) and 518.8+/-91.11 vs 97.6+/-17.81 pg ml(-1) (P <0.001), respectively]. In group II, there was a significant increase in serum and AF TNF-alpha at the end of follow-up compared to at first admission (P <0.001). The relative risk of death, hepatorenal syndrome (HRS) and spontaneous bacterial peritonitis (SBP) was higher in patients with bacterial DNA compared to those without bacterial DNA. We conclude that cirrhotic patients with culture-negative, non-neutrocytic ascites and bacterial DNA have a significantly higher level of serum and AF TNF-alpha and higher risk of HRS, SBP and mortality compared to those without bacterial DNA, suggesting that bacterial DNA and TNF-alpha are implicated in these complications of liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018026     DOI: 10.1099/jmm.0.2008/001867-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  14 in total

1.  Characterisation of bacteria in ascites--reporting the potential of culture-independent, molecular analysis.

Authors:  G B Rogers; L E Russell; P G Preston; P Marsh; J E Collins; J Saunders; J Sutton; D Fine; K D Bruce; M Wright
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-18       Impact factor: 3.267

2.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 3.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

4.  Application of qualitative and quantitative real-time PCR, direct sequencing, and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites.

Authors:  Sandra Krohn; Stephan Böhm; Cornelius Engelmann; Jan Hartmann; Annika Brodzinski; Antonis Chatzinotas; Katharina Zeller; Delia Prywerek; Ingo Fetzer; Thomas Berg
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

5.  The diagnostic value of neutrophil gelatinase-associated lipocalin and hepcidin in bacteria translocation of liver cirrhosis.

Authors:  Jiangguo Zhang; Fengyun Gong; Ling Li; Manzhi Zhao; Zhuhua Wu; Jianxin Song
Journal:  Int J Clin Exp Med       Date:  2015-09-15

6.  Expression of α-Defensins, CD20+ B-lymphocytes, and Intraepithelial CD3+ T-lymphocytes in the Intestinal Mucosa of Patients with Liver Cirrhosis: Emerging Mediators of Intestinal Barrier Function.

Authors:  Georgios I Tsiaoussis; Eleni C Papaioannou; Eleni P Kourea; Stelios F Assimakopoulos; Georgios I Theocharis; Michalis Petropoulos; Vasileios I Theopistos; Georgia G Diamantopoulou; Zoi Lygerou; Iris Spiliopoulou; Konstantinos C Thomopoulos
Journal:  Dig Dis Sci       Date:  2018-06-07       Impact factor: 3.199

7.  TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis.

Authors:  Glenda Trujillo; Alessia Meneghin; Kevin R Flaherty; Lynette M Sholl; Jeffrey L Myers; Ella A Kazerooni; Barry H Gross; Sameer R Oak; Ana Lucia Coelho; Holly Evanoff; Elizabeth Day; Galen B Toews; Amrita D Joshi; Matthew A Schaller; Beatrice Waters; Gabor Jarai; John Westwick; Steven L Kunkel; Fernando J Martinez; Cory M Hogaboam
Journal:  Sci Transl Med       Date:  2010-11-10       Impact factor: 17.956

Review 8.  Markers of bacterial translocation in end-stage liver disease.

Authors:  Ioannis Koutsounas; Garyfallia Kaltsa; Spyros I Siakavellas; Giorgos Bamias
Journal:  World J Hepatol       Date:  2015-09-18

9.  Translocation of bacterial NOD2 agonist and its link with inflammation.

Authors:  Oh Yoen Kim; Antoine Monsel; Michèle Bertrand; Jean-Marc Cavaillon; Pierre Coriat; Minou Adib-Conquy
Journal:  Crit Care       Date:  2009-07-28       Impact factor: 9.097

10.  Identification of bacterial pathogens in ascitic fluids from patients with suspected spontaneous bacterial peritonitis by use of broad-range PCR (16S PCR) coupled with high-resolution melt analysis.

Authors:  Justin Hardick; Helen Won; Kevin Jeng; Yu-Hsiang Hsieh; Charlotte A Gaydos; Richard E Rothman; Samuel Yang
Journal:  J Clin Microbiol       Date:  2012-05-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.